BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 19474722)

  • 1. The metabolic syndrome: how it may influence hepatic stellate cell activation and hepatic fibrosis.
    Lanthier N; Horsmans Y; Leclercq IA
    Curr Opin Clin Nutr Metab Care; 2009 Jul; 12(4):404-11. PubMed ID: 19474722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver fibrogenesis and metabolic factors.
    Anty R; Lemoine M
    Clin Res Hepatol Gastroenterol; 2011 Jun; 35 Suppl 1():S10-20. PubMed ID: 21742296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An adipocentric view of liver fibrosis and cirrhosis.
    Chuang JH; Wang PW; Tai MH
    Chang Gung Med J; 2004 Dec; 27(12):855-68. PubMed ID: 15754775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease.
    Schäffler A; Schölmerich J; Büchler C
    Nat Clin Pract Gastroenterol Hepatol; 2005 Jun; 2(6):273-80. PubMed ID: 16265231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the renin-angiotensin system in liver fibrosis.
    Munshi MK; Uddin MN; Glaser SS
    Exp Biol Med (Maywood); 2011 May; 236(5):557-66. PubMed ID: 21508249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners.
    Radaeva S; Sun R; Jaruga B; Nguyen VT; Tian Z; Gao B
    Gastroenterology; 2006 Feb; 130(2):435-52. PubMed ID: 16472598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of adipocytokines in hepatic fibrogenesis.
    Ikejima K; Okumura K; Kon K; Takei Y; Sato N
    J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S87-92. PubMed ID: 17567476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic steatohepatitis and metabolic syndrome.
    Machado M; Cortez-Pinto H
    Curr Opin Clin Nutr Metab Care; 2006 Sep; 9(5):637-42. PubMed ID: 16912563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokines and renin-angiotensin system signaling in hepatic fibrosis.
    Moreno M; Bataller R
    Clin Liver Dis; 2008 Nov; 12(4):825-52, ix. PubMed ID: 18984469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolving role of leptin and adiponectin in chronic liver diseases.
    Tsochatzis E; Papatheodoridis GV; Archimandritis AJ
    Am J Gastroenterol; 2006 Nov; 101(11):2629-40. PubMed ID: 16952281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications.
    Friedman SL
    Nat Clin Pract Gastroenterol Hepatol; 2004 Dec; 1(2):98-105. PubMed ID: 16265071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome.
    Maury E; Brichard SM
    Mol Cell Endocrinol; 2010 Jan; 314(1):1-16. PubMed ID: 19682539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences.
    Leclercq IA; Da Silva Morais A; Schroyen B; Van Hul N; Geerts A
    J Hepatol; 2007 Jul; 47(1):142-56. PubMed ID: 17512085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of the metabolic syndrome, hepatic steatosis and steatohepatitis on liver fibrosis in hereditary hemochromatosis.
    Adams LA; Angulo P; Abraham SC; Torgerson H; Brandhagen D
    Liver Int; 2006 Apr; 26(3):298-304. PubMed ID: 16584391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms of hepatic fibrosis in non-alcoholic steatohepatitis.
    Rombouts K; Marra F
    Dig Dis; 2010; 28(1):229-35. PubMed ID: 20460917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fructose: a highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome.
    Dekker MJ; Su Q; Baker C; Rutledge AC; Adeli K
    Am J Physiol Endocrinol Metab; 2010 Nov; 299(5):E685-94. PubMed ID: 20823452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.
    Rafiq N; Younossi ZM
    Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):207-15. PubMed ID: 19072356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
    Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
    Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: non-alcoholic fatty liver disease and hepatitis C--risk factors and clinical implications.
    Sanyal AJ
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():48-51. PubMed ID: 16225473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics.
    Tietge UJ; Böker KH; Manns MP; Bahr MJ
    Am J Physiol Endocrinol Metab; 2004 Jul; 287(1):E82-9. PubMed ID: 15010338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.